stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / HALO / Net Income

Halozyme Therapeutics, Inc. Net Income 2009–2025

Halozyme Therapeutics, Inc. (HALO) annual net income by fiscal year, computed from SEC filings.

Fiscal yearNet IncomeNet marginChange (YoY)
FY 2025$316.89M22.7%-28.6%
FY 2024$444.09M43.7%+57.7%
FY 2023$281.59M34.0%+39.3%
FY 2022$202.13M30.6%-49.8%
FY 2021$402.71M90.8%+212.0%
FY 2020$129.09M48.2%+278.7%
FY 2019$-72.24M-36.9%+10.1%
FY 2018$-80.33M-52.9%-227.6%
FY 2017$62.97M19.9%+161.1%
FY 2016$-103.02M-70.2%-219.6%
FY 2015$-32.23M-23.9%+52.9%
FY 2014$-68.38M-90.8%+18.1%
FY 2013$-83.48M-152.3%-55.9%
FY 2012$-53.55M-126.5%-170.9%
FY 2011$-19.77M-35.2%+62.9%
FY 2010$-53.24M-390.8%+8.8%
FY 2009$-58.36M-426.9%

Source: Halozyme Therapeutics, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Halozyme Therapeutics, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Halozyme Therapeutics, Inc. — frequently asked questions

What is Halozyme Therapeutics, Inc.'s net income?

Halozyme Therapeutics, Inc. (HALO) reported net income of $316.89M for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More HALO financial history

Full HALO fundamentals page → · All 1,500+ companies →